touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the later-line treatment options for chronic myeloid leukaemia, including T315I mutation-positive disease
The multidisciplinary team
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis. This medical education is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/mdt-management-cml-later-line-setting-holistic-approach/
